1. GARP: a key receptor controlling FOXP3 in human regulatory T cells.
- Author
-
Probst-Kepper, M., Geffers, R., Kröger, A., Viegas, N., Erck, C., Hecht, H.-J., Lünsdorf, H., Roubin, R., Moharregh-Khiabani, D., Wagner, K., Ocklenburg, F., Jeron, A., Garritsen, H., Arstila, T. P., Kekäläinen, E., Balling, R., Hauser, H., Buer, J., and Weiss, S.
- Subjects
T cells ,REGULATION of cell growth ,CELLULAR control mechanisms ,LYMPHOCYTES ,GENOTYPE-environment interaction - Abstract
Recent evidence suggests that regulatory pathways might control sustained high levels of FOXP3 in regulatory CD4
+ CD25hi T (Treg ) cells. Based on transcriptional profiling of ex vivo activated Treg and helper CD4+ CD25− T (Th ) cells we have identified GARP (glycoprotein-A repetitions predominant), LGALS3 (lectin, galactoside-binding, soluble, 3) and LGMN (legumain) as novel genes implicated in human Treg cell function, which are induced upon T-cell receptor stimulation. Retroviral overexpression of GARP in antigen-specific Th cells leads to an efficient and stable re-programming of an effector T cell towards a regulatory T cell, which involves up-regulation of FOXP3, LGALS3, LGMN and other Treg -associated markers. In contrast, overexpression of LGALS3 and LGMN enhance FOXP3 and GARP expression, but only partially induced a regulatory phenotype. Lentiviral down-regulation of GARP in Treg cells significantly impaired the suppressor function and was associated with down-regulation of FOXP3. Moreover, down-regulation of FOXP3 resulted in similar phenotypic changes and down-regulation of GARP. This provides compelling evidence for a GARP-FOXP3 positive feedback loop and provides a rational molecular basis for the known difference between natural and transforming growth factor-β induced Treg cells as we show here that the latter do not up-regulate GARP. In summary, we have identified GARP as a key receptor controlling FOXP3 in Treg cells following T-cell activation in a positive feedback loop assisted by LGALS3 and LGMN, which represents a promising new system for the therapeutic manipulation of T cells in human disease. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF